United Capital Financial Advisers LLC Trims Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

United Capital Financial Advisers LLC reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 98,982 shares of the medical research company’s stock after selling 1,339 shares during the quarter. United Capital Financial Advisers LLC’s holdings in Thermo Fisher Scientific were worth $29,069,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TMO. Vontobel Swiss Wealth Advisors AG acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $3,347,000. Pinnacle Financial Partners Inc. raised its position in shares of Thermo Fisher Scientific by 14.9% during the 1st quarter. Pinnacle Financial Partners Inc. now owns 4,687 shares of the medical research company’s stock valued at $1,283,000 after acquiring an additional 609 shares in the last quarter. Hall Laurie J Trustee raised its position in shares of Thermo Fisher Scientific by 2.4% during the 1st quarter. Hall Laurie J Trustee now owns 2,148 shares of the medical research company’s stock valued at $588,000 after acquiring an additional 50 shares in the last quarter. Grimes & Company Inc. raised its position in shares of Thermo Fisher Scientific by 18.7% during the 1st quarter. Grimes & Company Inc. now owns 1,094 shares of the medical research company’s stock valued at $299,000 after acquiring an additional 172 shares in the last quarter. Finally, Gabelli Funds LLC raised its position in shares of Thermo Fisher Scientific by 9.9% during the 1st quarter. Gabelli Funds LLC now owns 148,750 shares of the medical research company’s stock valued at $40,716,000 after acquiring an additional 13,350 shares in the last quarter. Institutional investors own 88.19% of the company’s stock.

TMO has been the topic of several analyst reports. BTIG Research increased their target price on Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Monday, July 15th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 target price on the stock in a research report on Wednesday, June 12th. Wolfe Research initiated coverage on Thermo Fisher Scientific in a research report on Thursday, May 30th. They issued an “outperform” rating on the stock. Finally, UBS Group increased their target price on Thermo Fisher Scientific from $305.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, May 23rd. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $303.17.

Shares of TMO traded up $1.08 during trading hours on Friday, reaching $296.05. 465,409 shares of the company’s stock traded hands, compared to its average volume of 1,402,373. The firm has a market capitalization of $115.94 billion, a price-to-earnings ratio of 26.62, a P/E/G ratio of 1.89 and a beta of 1.12. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.07. Thermo Fisher Scientific Inc. has a twelve month low of $208.34 and a twelve month high of $305.45. The business’s fifty day simple moving average is $280.90 and its two-hundred day simple moving average is $276.38.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, beating analysts’ consensus estimates of $3.01 by $0.03. The company had revenue of $6.32 billion for the quarter, compared to analyst estimates of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company earned $2.75 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 12.24 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, September 17th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.83%.

In other news, Director Jim P. Manzi sold 1,833 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $272.93, for a total transaction of $500,280.69. Following the transaction, the director now directly owns 28,592 shares of the company’s stock, valued at $7,803,614.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $284.83, for a total value of $14,241,500.00. Following the transaction, the chief executive officer now directly owns 342,193 shares in the company, valued at $97,466,832.19. The disclosure for this sale can be found here. 0.45% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Featured Article: How do CD ladders protect against rising interest rates?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.